Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Opinion and Comment
Nature Biotechnology 25, 1390–1393 (1 December 2007) | doi:10.1038/nbt1207-1390
Antivirals|[mdash]|an increasingly healthy investment
Abstract
The antiviral sector offers unmet medical needs, large patient markets, suboptimal standards of care and substantial profits for successful drug candidates. It is an area where biotech companies that advance drug candidates into clinical development can attract pharmaceutical partners.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
